Experimental Autoimmune Myasthenia Gravis (Autoimmune Experimental Myasthenia Gravis)

Subscribe to Selected New Research on Experimental Autoimmune Myasthenia Gravis

382 relevant articles (10 outcomes, 29 trials/studies) found for this Disease

Description: Any autoimmune animal disease model used in the study of MYASTHENIA GRAVIS. Injection with purified neuromuscular junction acetylcholine receptor (AChR) (see RECEPTORS, CHOLINERGIC) components results in a myasthenic syndrome that has acute and chronic phases. The motor endplate pathology, loss of acetylcholine receptors, presence of circulating anti-AChR antibodies, and electrophysiologic changes make this condition virtually identical to human myasthenia gravis. Passive transfer of AChR antibodies or lymphocytes from afflicted animals to normals induces passive transfer experimental autoimmune myasthenia gravis. (From Joynt, Clinical Neurology, 1997, Ch 54, p3)

Also Known As:

Autoimmune Experimental Myasthenia Gravis; Myasthenia Gravis, Autoimmune, Experimental; Experimental Autoimmune Myasthenia Gravis, Passive Transfer; Experimental Myasthenia; Experimental Myasthenia Gravis; Myasthenia Gravis, Autoimmune Experimental; Experimental Myasthenias; Myasthenia Gravis, Experimental; Myasthenia, Experimental; Myasthenias, Experimental; Myasthenia Gravis, Experimental Autoimmune; Passive Transfer Experimental Autoimmune Myasthenia Gravis

Relationship Network

Disease Context: Research Results

Nervous System Diseases: 3406

Neuromuscular Diseases: 742

Neuromuscular Junction Diseases: 20

Myasthenia Gravis: 4315

Experimental Autoimmune Myasthenia Gravis: 382

Autoimmune Diseases of the Nervous System: 16

Myasthenia Gravis: 4315

Experimental Autoimmune Myasthenia Gravis: 382

Experimental Nervous System Autoimmune Disease: 11

Experimental Autoimmune Myasthenia Gravis: 382

Immune System Diseases: 1232

Autoimmune Diseases: 11535

Autoimmune Diseases of the Nervous System: 16

Myasthenia Gravis: 4315

Experimental Autoimmune Myasthenia Gravis: 382

Experimental Nervous System Autoimmune Disease: 11

Experimental Autoimmune Myasthenia Gravis: 382

Related Diseases

1.	Myasthenia Gravis
2.	Type 1 Diabetes Mellitus (Autoimmune Diabetes)
3.	Autoimmune Diseases (Autoimmune Disease)
4.	Inborn Genetic Diseases (Disease, Hereditary)
5.	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
35 Diseases and 65 more articles analyzed in the Research Interface, order at left...

Experts

1.	Fuchs, Sara: 9 articles (09/2008 - 02/2003)
2.	Feferman, Tali: 8 articles (09/2008 - 07/2003)
3.	Souroujon, Miriam C: 8 articles (09/2008 - 07/2003)
4.	Christadoss, Premkumar: 7 articles (02/2008 - 01/2002)
5.	Link, H: 4 articles (11/2004 - 05/2000)
6.	Goluszko, Elzbieta: 4 articles (04/2003 - 01/2002)
7.	Barchan, D: 4 articles (10/2001 - 10/2000)
8.	Fuchs, S: 4 articles (10/2001 - 10/2000)
9.	Im, S H: 4 articles (10/2001 - 10/2000)
10.	Souroujon, M C: 4 articles (10/2001 - 10/2000)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Experimental Autoimmune Myasthenia Gravis:

1.	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 02/01/1999 - "The authors performed the study to establish an animal model of experimental autoimmune myasthenia gravis (EAMG) by immunizing the nicotinic acetylcholine receptor (AChR) and to understand CD5+ B-lymphocyte changes in peripheral blood of EAMGs" 07/15/1993 - "Experimental autoimmune myasthenia gravis is induced in C57BL/6 mice by injection of Torpedo nicotinic acetylcholine receptor (TAChR)" 01/15/1993 - "The main immunogenic region (MIR) of the nicotinic acetylcholine receptor (AChR) is an immunodominant area of the molecule, both in human and in experimental autoimmune myasthenia gravis" 08/31/1992 - "A quantitative evaluation was made of nicotinic acetylcholine receptors (AChR) at the motor end-plates in experimental autoimmune myasthenia gravis (EAMG)" 02/01/1992 - "In experimental autoimmune myasthenia gravis anti-rat nicotinic acetylcholine receptor (AChR) antibody titers correlated significantly with the AChR-antibody complexes found in muscle" Get all the results and reference details, order at left...
2.	Chaperonin 60IBA 03/01/2000 - "Some study results indicate that mucosal tolerance induced by appropriate recombinant peptide fragments of human AChR is effective in suppressing experimental autoimmune myasthenia gravis and might be considered as a therapeutic modality for patients with MG. A peptide of the heat-shock protein 60 molecule, designated peptide p277, was shown to be a target of T cells in autoimmune diabetes in NOD mice, and intraperitoneal injections of glutamic acid decarboxylase (GAD) peptide 524-543 delayed the onset of diabetes and significantly reduced its incidence" Get all the results and reference details, order at left...
3.	Peptide FragmentsIBA 03/01/2000 - "Some study results indicate that mucosal tolerance induced by appropriate recombinant peptide fragments of human AChR is effective in suppressing experimental autoimmune myasthenia gravis and might be considered as a therapeutic modality for patients with MG. A peptide of the heat-shock protein 60 molecule, designated peptide p277, was shown to be a target of T cells in autoimmune diabetes in NOD mice, and intraperitoneal injections of glutamic acid decarboxylase (GAD) peptide 524-543 delayed the onset of diabetes and significantly reduced its incidence" Get all the results and reference details, order at left...
4.	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 03/01/2000 - "Some study results indicate that mucosal tolerance induced by appropriate recombinant peptide fragments of human AChR is effective in suppressing experimental autoimmune myasthenia gravis and might be considered as a therapeutic modality for patients with MG. A peptide of the heat-shock protein 60 molecule, designated peptide p277, was shown to be a target of T cells in autoimmune diabetes in NOD mice, and intraperitoneal injections of glutamic acid decarboxylase (GAD) peptide 524-543 delayed the onset of diabetes and significantly reduced its incidence" Get all the results and reference details, order at left...
5.	PeptidesIBA 02/01/2006 - "We have investigated the efficacy of immunization against peptides from predisposing MHC class II molecules in human-compatible adjuvants for ameliorating experimental autoimmune myasthenia gravis (EAMG)" 07/01/2004 - "Immunodominant T and B cell determinants did not induce experimental autoimmune myasthenia gravis (EAMG), although immunization resulted in strong Th1 and B cell responses, which could be mapped with overlapping peptides of the nAChR epsilon-subunit in eight different rat strains" 11/01/1999 - "No data are yet available on oral tolerance with immunodominant T-cell peptides in experimental autoimmune myasthenia gravis (EAMG), an animal model of B cell-dependent disease" 05/13/1998 - "Coimmunization of MHC class II competitor peptides during experimental autoimmune myasthenia gravis induction resulted not only in a suppressed, but also in an altered immune response." 05/01/1998 - "Synthetic peptides fail to induce nasal tolerance to experimental autoimmune myasthenia gravis." Get all the results and reference details, order at left...
6.	Freund's AdjuvantIBA 02/13/1996 - "Oral and nasal administration of nicotinic acetylcholine receptor (AChR) to Lewis rats prior to myasthenogenic immunization with AChR and complete Freund's adjuvant (CFA) resulted in prevention or marked decrease of the severity of experimental autoimmune myasthenia gravis (EAMG) and suppression of AChR-specific B-cell responses and of AChR-reactive T-cell function" 05/01/2006 - "Critical interactions between the nervous system and the immune system during experimental autoimmune myasthenia gravis (EAMG) were examined in an animal model for human MG after immunization of adult female Lewis rats with Torpedo acetylcholine receptor (AChR) and complete Freund's adjuvant" 02/01/2000 - "Animal models of experimental autoimmune myasthenia gravis (EAMG) can be induced in vertebrates by immunization with Torpedo californica acetylcholine receptors (AChR) in complete Freund's adjuvant" 05/01/1995 - "To understand the role of CD8+ T cells in experimental autoimmune myasthenia gravis (EAMG), CD8+ T cells were depleted by injecting a monoclonal anti-rat CD8 antibody (OX8) into Lewis rats immunized with Torpedo acetylcholine receptor (AChR) in complete Freund's adjuvant (CFA)" 05/01/1985 - "Experimental autoimmune myasthenia gravis (EAMG) was produced in rabbits by the injection of acetylcholine receptor (AChR) protein from electric organ of Narkacion tokyonis with complete Freund's adjuvant, and the ultrastructural alterations of the neuromuscular junctions were studied" Get all the results and reference details, order at left...
7.	Messenger RNA (mRNA)IBA 01/01/2008 - "In rats with experimental autoimmune myasthenia gravis (EAMG), inhibition of production of AChE-R using antisense is associated with a significant reduction in synaptic expression of AChE-R mRNA and protein, with improved muscle strength and stamina and increased survival" 11/26/1998 - "Cytokine and chemokine mRNA expressing cells in muscle tissues of experimental autoimmune myasthenia gravis." 06/20/1988 - "Our experiments indicate a specific increase (4-7-fold) in the levels of alpha-subunit mRNA in animals with experimental autoimmune myasthenia gravis (EAMG), in comparison with control animals" 02/13/1996 - "Mucosal tolerance to experimental autoimmune myasthenia gravis is associated with down-regulation of AChR-specific IFN-gamma-expressing Th1-like cells and up-regulation of TGF-beta mRNA in mononuclear cells." 06/20/1988 - "Increased levels of acetylcholine receptor alpha-subunit mRNA in experimental autoimmune myasthenia gravis." Get all the results and reference details, order at left...
8.	Immunosuppressive Agents (Immunosuppressants)IBA 10/01/1992 - "In the search for a new drug to treat myasthenia gravis, we studied the efficacy of new immunosuppressants on experimental autoimmune myasthenia gravis (EAMG)" 10/01/1992 - "Suppression of experimental autoimmune myasthenia gravis with new immunosuppressants: 15-deoxyspergualin and actinobolin." Get all the results and reference details, order at left...
9.	Dehydroepiandrosterone (DHEA)IBA 03/01/2003 - "Dehydroepiandrosterone therapy ameliorates experimental autoimmune myasthenia gravis in Lewis rats." 03/01/2003 - "To detect a possible effect of dehydroepiandrosterone (DHEA) in the pathogenesis of experimental autoimmune myasthenia gravis (EAMG), DHEA (0.5 mg/rat) was administrated intraperitoneally to Lewis rats every other day from day 4 postimmunization (p.i.) to day 35 p.i. with Torpedo acetylcholine receptor (AChR) and Freund's complete adjuvant" Get all the results and reference details, order at left...
10.	Cholinesterase Inhibitors (Anticholinesterases)IBA 10/01/2006 - "In rats with experimental autoimmune myasthenia gravis, oral delivery of Monarsen improved muscle action potential in a lower dose regimen (nanomolar versus micromolar), rapid and prolonged manner (up to 72 h versus 2-4 h) as compared with the currently used small molecule anticholinesterases" Get all the results and reference details, order at left...
158 Drugs and Important Bio-Agents and 377 more articles analyzed in the Research Interface, order at left...

Therapies and Procedures

1.	Lymphatic Irradiation 09/01/1990 - "Total lymphoid irradiation (TLI) is effective in the immunosuppressive treatment of human and experimental autoimmune disorders, including experimental autoimmune myasthenia gravis (EAMG)" 07/01/1988 - "Treatment of experimental myasthenia gravis with total lymphoid irradiation." 09/01/1990 - "Total lymphoid irradiation and antigen-specific tolerance: future therapy for experimental myasthenia gravis?" Get all the results and reference details, order at left...
2.	Immunotherapy 09/01/2003 - "Specific immunotherapy of experimental myasthenia by genetically engineered APCs: the "guided missile" strategy." 03/15/2001 - "Specific immunotherapy of experimental myasthenia gravis in vitro: the "guided missile" strategy." 07/01/1998 - "Immunotherapy of experimental autoimmune myasthenia gravis: selective effects of CTLA4Ig and synergistic combination with an IL2-diphtheria toxin fusion protein." 05/01/1998 - "In-line affinity chromatographic removal of specific antibody from rabbits with experimental myasthenia gravis as a prelude to immunotherapy." 08/01/1983 - "Combined short-term immunotherapy for experimental autoimmune myasthenia gravis." Get all the results and reference details, order at left...
3.	Denervation 05/01/2006 - "Modulation of immune responses and suppression of experimental autoimmune myasthenia gravis by surgical denervation of the spleen." 03/24/1992 - "The regulation of genes for acetylcholine receptor (AChR), myogenic factors and other muscle-specific proteins has been analyzed in experimental autoimmune myasthenia gravis (EAMG) and following denervation" Get all the results and reference details, order at left...
4.	Bone Marrow Transplantation (Transplantation, Bone Marrow) 09/01/2003 - "Experimental autoimmune myasthenia gravis (EAMG) can be induced in a large number of animal species by active immunization (AI) AChR, by passive transfer (PT) of anti-AChR antibodies, by autologous bone marrow transplantation and cyclosporin (BMT-Cy), or spontaneously" Get all the results and reference details, order at left...
5.	Thymectomy 04/01/1970 - "The effect of thymectomy, hemi-thymectomy and sham thymectomy on experimental myasthenia gravis in guinea-pigs." Get all the results and reference details, order at left...
7 Therapies and Procedures and 16 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>